Premium
Checkpoint blockade in esophagogastric cancer
Author(s) -
Cohen Noah A.,
Strong Vivian E.,
Janjigian Yelena Y.
Publication year - 2018
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.25116
Subject(s) - medicine , blockade , esophagogastric junction , pembrolizumab , immune checkpoint , cancer , oncology , adenocarcinoma , chemotherapy , immunotherapy , receptor
There are few effective treatment options for metastatic esophagogastric adenocarcinomas after progression on second‐line chemotherapy. Immune checkpoint blockade therapy is a promising treatment strategy for selected advanced esophagogastric cancer, and the PD‐1 inhibitor pembrolizumab has recently been approved for metastatic or recurrent gastric or gastroesophageal junction cancer that has progressed beyond second‐line systemic therapy. We review the current data supporting immune checkpoint blockade therapy in advanced esophagogastric adenocarcinoma.